22 results on '"R, Rivera Díaz"'
Search Results
2. Implementación de las recomendaciones sobre las actuaciones a seguir durante la edad fértil, el embarazo, el posparto, la lactancia y el cuidado perinatal en pacientes con psoriasis
- Author
-
I. Belinchón, S. Armesto, P. de la Cueva, L. Ferrándiz, R. Rivera Díaz, and J.M. Carrascosa
- Subjects
Psoriasis ,Fertility ,Pregnancy ,Postpartum ,Breastfeeding ,Recommendations ,Dermatology ,RL1-803 ,Internal medicine ,RC31-1245 - Abstract
Resumen: Objetivo: Analizar el grado de implementación de las recomendaciones del Grupo de Psoriasis (GPS) sobre las actuaciones a seguir durante la edad fértil, el embarazo, el posparto, la lactancia y el cuidado perinatal en la psoriasis. Métodos: Se diseñó y envió una encuesta cerrada, estructurada y anónima, en formato electrónico a miembros del GPS a través del correo electrónico. Se recogieron las variables sociodemográficas y profesionales de los participantes, y otras relacionadas con los objetivos propuestos. Se realizó un análisis descriptivo. Resultados: Se analizaron 53 encuestas. El 96% de los participantes conocen las recomendaciones del GPS, pero su nivel de participación en unidades de atención multidisciplinar o la disposición de protocolos específicos en los servicios es muy baja. El 70% pregunta de forma regular sobre el deseo gestacional, aunque solo el 46% lo pregunta a varones y mujeres. Se ofrece consejo preconcepcional más a mujeres que a varones (54 vs. 19%). Gran variabilidad en cuanto a los consejos ofrecidos. El 90% suspende tratamientos tópicos durante el embarazo, y prácticamente el 100% los tratamientos sistémicos salvo la ciclosporina A. En el tercer trimestre se suspenden la mayoría de las terapias biológicas a excepción de certolizumab pegol. Los tratamientos tópicos, fototerapia y certolizumab pegol son usados casi por el 100% de los encuestados en la lactancia. La falta de tiempo, de apoyo de los gestores y de datos robustos son las principales limitaciones a la implementación de las recomendaciones. Conclusiones: A pesar de que son ampliamente conocidas, las recomendaciones del GPS aún quedan áreas de mejora. Abstract: Objective: To analyze degree of implementation of recommendations on the management of psoriasis during preconception, pregnancy, postpartum, breastfeeding, and perinatal care published by the Psoriasis Working Group of the Spanish Academy of Dermatology and Venereology (AEDV). Methods: We designed a structured online survey consisting of closed questions. A link was emailed to all the members of the Psoriasis Working Group to collect their anonymous responses. We also collected sociodemographic, professional, and practice-related data related to the goals of the study and then compiled descriptive statistics to analyze the survey findings. Results: We received 53 responses for analysis. Overall, 96% of respondents were familiar with the recommendations, but very few of them worked in multidisciplinary maternity care units or had access to specific protocols on the management of psoriasis before, during, and after pregnancy in their departments. Seventy percent of dermatologists regularly ask their patients about pregnancy plans, but only 46% ask both men and women. Women also receive more preconception advice than men (54% vs. 19%). Significant variations were observed in the type of advice given. Ninety percent of the dermatologists interrupt topical treatments during pregnancy, and nearly all suspend conventional systemic drugs with the exception of cyclosporin A. Most biologics are also being discontinued in the third trimester, with the exception of certolizumab pegol. Almost all the respondents indicated that they use topical treatments, phototherapy, and certolizumab pegol in breastfeeding mothers. The main barriers to implementing the working group's recommendations are a lack of time, a lack of support, and a lack of robust data. Conclusions: Although the AEDV psoriasis working group's recommendations are widely known, areas for improvement remain.
- Published
- 2022
- Full Text
- View/download PDF
3. [Artículo traducido] Los inhibidores selectivos de la IL23 son, en su mayoría, efectivos y seguros en pacientes con psoriasis y fallo previo a tratamientos biológicos anti IL-17. Una experiencia de práctica clínica real a 52 semanas
- Author
-
J. Arroyo-Andrés, D. Falkenhain-López, M. Agud-Dios, and R. Rivera-Díaz
- Subjects
Dermatology ,RL1-803 ,Internal medicine ,RC31-1245 - Published
- 2023
- Full Text
- View/download PDF
4. Psoriasis moderada-grave en pacientes pediátricos y jóvenes: experiencia en el registro BIOBADADERM
- Author
-
L.M. Nieto Benito, G. Carretero, R. Rivera-Díaz, J.M. Carrascosa, E. Daudén, P. de la Cueva, A. Sahuquillo-Torralba, E. Herrera-Acosta, O. Baniandrés-Rodríguez, J.L. Lopez-Estebaranz, I. Belinchón, J. Riera-Monroig, M. Ferrán, F.J. Gómez-García, A. Mateu, L. Rodríguez, J. Vilar-Alejo, C. García-Donoso, F. Ballescá, Llamas-M. Velasco, R. Botella-Estrada, E. Herrera-Ceballos, D.P. Ruiz-Genao, M.A. Descalzo, and I. García-Doval
- Subjects
BIOBADADERM ,Childhood ,Psoriasis ,Registries ,Dermatology ,RL1-803 ,Internal medicine ,RC31-1245 - Abstract
Resumen: El comienzo de la psoriasis en la edad pediátrica, aunque generalmente leve, puede requerir tratamiento sistémico en las formas moderadas o graves de la enfermedad. El objetivo de este trabajo es analizar la frecuencia relativa, las características de los pacientes, el tratamiento empleado y los eventos adversos (EA) observados a partir del registro BIOBADADERM en niños y jóvenes con psoriasis moderada-grave. Del total de 3.946 pacientes del registro, se incluyen 24 pacientes menores de 21 años, con una edad media al inicio del tratamiento en BIOBADADERM de 16,1 años y un PASI medio de 9,4. El 67% de los pacientes estaba en tratamiento sistémico clásico al inicio del registro. Catorce pacientes (58%) suspendieron el tratamiento por pérdida o falta de eficacia o por EA. En conclusión, los datos del registro BIOBADADERM muestran que los menores representan un grupo muy pequeño dentro de los pacientes con psoriasis que reciben tratamiento sistémico y son manejados más frecuentemente con tratamientos clásicos. Abstract: Childhood-onset psoriasis generally follows an indolent course but patients with moderate or severe disease may require systemic treatment. The aim of this study was to determine the relative proportion of children and young people aged up to 21 years with moderate to severe psoriasis in the BIOBADADERM registry and to analyze the characteristics of these patients, treatments used, and adverse events. Of the 3946 patients in the registry, 24 were aged 21 years or younger. They had mean age of 16.1 years on starting treatment. When the registry was started, they had a Psoriasis Area and Severity Index of 9.4 and 67% were being treated with a conventional systemic drug. Treatment was discontinued in 14 patients (58%) due to adverse events or a loss or lack of effectiveness. In conclusion, the BIOBADADERM registry shows that young people account for a small proportion of psoriasis patients receiving systemic treatment, and they are more likely to be treated using conventional systemic drugs.
- Published
- 2022
- Full Text
- View/download PDF
5. Condilomas acuminados resistentes a los tratamientos convencionales con buena respuesta a tratamiento con terapia fotodinámica
- Author
-
B. Pinilla Martín, R. Rivera Díaz, and V. Monsálvez Honrubia
- Subjects
Dermatology ,RL1-803 ,Internal medicine ,RC31-1245 - Published
- 2022
- Full Text
- View/download PDF
6. [Translated article] Implementation of Recommendations for the Management of Psoriasis During Preconception, Pregnancy, Postpartum, Breastfeeding, and Perinatal Care
- Author
-
I. Belinchón, S. Armesto, P. de la Cueva, L. Ferrándiz, R. Rivera Díaz, and J.M. Carrascosa
- Subjects
Psoriasis ,Fertilidad ,Embarazo ,Posparto ,Lactancia ,Recomendaciones ,Dermatology ,RL1-803 ,Internal medicine ,RC31-1245 - Abstract
Objective: To analyze degree of implementation of recommendations on the management of psoriasis during preconception, pregnancy, postpartum, breastfeeding, and perinatal care published by the Psoriasis Working Group of the Spanish Academy of Dermatology and Venereology (AEDV). Methods: We designed a structured online survey consisting of closed questions. A link was emailed to all the members of the Psoriasis Working Group to collect their anonymous responses. We also collected sociodemographic, professional, and practice-related data related to the goals of the study and then compiled descriptive statistics to analyze the survey findings. Results: We received 53 responses for analysis. Overall, 96% of respondents were familiar with the recommendations, but very few of them worked in multidisciplinary maternity care units or had access to specific protocols on the management of psoriasis before, during, and after pregnancy in their departments. Seventy percent of dermatologists regularly ask their patients about pregnancy plans, but only 46% ask both men and women. Women also receive more preconception advice than men (54% vs. 19%). Significant variations were observed in the type of advice given. Ninety percent of the dermatologists interrupt topical treatments during pregnancy, and nearly all suspend conventional systemic drugs with the exception of cyclosporin A. Most biologics are also being discontinued in the third trimester, with the exception of certolizumab pegol. Almost all the respondents indicated that they use topical treatments, phototherapy, and certolizumab pegol in breastfeeding mothers. The main barriers to implementing the working group's recommendations are a lack of time, a lack of support, and a lack of robust data. Conclusions: Although the AEDV psoriasis working group's recommendations are widely known, areas for improvement remain. Resumen: Objetivo: Analizar el grado de implementación de las recomendaciones del Grupo de Psoriasis (GPS) sobre las actuaciones a seguir durante la edad fértil, el embarazo, el posparto, la lactancia y el cuidado perinatal en la psoriasis. Métodos: Se diseñó y envió una encuesta cerrada, estructurada y anónima, en formato electrónico a miembros del GPS a través del correo electrónico. Se recogieron las variables sociodemográficas y profesionales de los participantes, y otras relacionadas con los objetivos propuestos. Se realizó un análisis descriptivo. Resultados: Se analizaron 53 encuestas. El 96% de los participantes conocen las recomendaciones del GPS, pero su nivel de participación en unidades de atención multidisciplinar o la disposición de protocolos específicos en los servicios es muy baja. El 70% pregunta de forma regular sobre el deseo gestacional, aunque solo el 46% lo pregunta a varones y mujeres. Se ofrece consejo preconcepcional más a mujeres que a varones (54 vs. 19%). Gran variabilidad en cuanto a los consejos ofrecidos. El 90% suspende tratamientos tópicos durante el embarazo, y prácticamente el 100% los tratamientos sistémicos salvo la ciclosporina A. En el tercer trimestre se suspenden la mayoría de las terapias biológicas a excepción de certolizumab pegol. Los tratamientos tópicos, fototerapia y certolizumab pegol son usados casi por el 100% de los encuestados en la lactancia. La falta de tiempo, de apoyo de los gestores y de datos robustos son las principales limitaciones a la implementación de las recomendaciones. Conclusiones: A pesar de que son ampliamente conocidas, las recomendaciones del GPS aún quedan áreas de mejora.
- Published
- 2022
- Full Text
- View/download PDF
7. Consenso sobre las actuaciones a seguir durante la edad fértil, el embarazo, el posparto y la lactancia en pacientes con psoriasis
- Author
-
I. Belinchón, M. Velasco, M. Ara-Martín, S. Armesto Alonso, O. Baniandrés Rodríguez, L. Ferrándiz Pulido, M. García-Bustinduy, J.A. Martínez-López, N. Martínez Sánchez, A. Pérez Ferriols, E. Pérez Pascual, R. Rivera Díaz, R. Ruiz-Villaverde, R. Taberner Ferrer, A. Vicente Villa, and J.M. Carrascosa
- Subjects
Psoriasis ,Fertility ,Pregnancy ,Postpartum ,Breastfeeding ,Delphi process ,Dermatology ,RL1-803 ,Internal medicine ,RC31-1245 - Abstract
Resumen: Objetivo: Desarrollar recomendaciones basadas en la mejor evidencia y experiencia sobre el manejo de pacientes con psoriasis durante la edad fértil, el embarazo, el posparto y la lactancia. Métodos: Se siguió la metodología de grupos nominales y Delphi. Se seleccionó un grupo director de expertos (12 dermatólogos —de los cuales 2 fueron los coordinadores—, 1 reumatólogo, 2 ginecólogos). Se realizó una revisión sistemática de la literatura sobre fertilidad, embarazo, posparto y lactancia en pacientes con psoriasis. Con esta información los coordinadores generaron una serie de recomendaciones preliminares. Todo ello se presentó y discutió con el resto de expertos en una reunión de grupo nominal donde se definió el alcance, los usuarios, los apartados del documento, y donde se generaron las recomendaciones definitivas. El grado de acuerdo con las recomendaciones se votó siguiendo la metodología Delphi, que se extendió a 51 dermatólogos más, según una escala de 1 (total desacuerdo) a 10 (total acuerdo), definiéndose el acuerdo como una puntuación ≥ 7 por al menos el 70% de los participantes. El nivel de evidencia y el grado de recomendación se clasificaron según el modelo del Center for Evidence Based Medicine de Oxford. El documento completo final fue aprobado por el panel de expertos. Resultados: Se generaron 23 recomendaciones sobre el periodo pre-concepcional (fertilidad y anticoncepción), el embarazo (planificación, manejo farmacológico y seguimiento) y la lactancia (manejo y seguimiento). Todas las recomendaciones menos una alcanzaron el nivel de acuerdo definido. Conclusiones: En los pacientes con psoriasis en edad fértil estas recomendaciones pueden mejorar el manejo, los resultados y el pronóstico. Abstract: Objective: To develop evidence- and experience-based recommendations for the management of psoriasis during preconception, pregnancy, postpartum, and breastfeeding. Methods: The nominal group technique and the Delphi method were used. Fifteen experts (12 dermatologists, 2 of whom were appointed coordinators; 1 rheumatologist; and 2 gynecologists) were selected to form an expert panel. Following a systematic review of the literature on fertility, pregnancy, postpartum, and breastfeeding in women with psoriasis, the coordinators drew up a series of preliminary recommendations for discussion by the panel at a nominal group meeting. The experts defined the scope, sections, and intended users of the statement and prepared a final list of recommendations. Consensus was obtained using a Delphi process in which an additional 51 dermatologists rated their level of agreement with each recommendation on a scale of 1 (total disagreement) to 10 (total agreement). Consensus was defined by a score of 7 or higher assigned by at least 70% of participants. Level of evidence and strength of recommendation were reported using the Oxford Center for Evidence-Based Medicine categories. The final statement was approved by the expert panel. Results: The resulting consensus statement includes 23 recommendations on preconception (fertility and contraception), pregnancy (planning, pharmacological management, and follow-up), and breastfeeding (management and follow-up). Consensus was achieved for all recommendations generated except one. Conclusions: These recommendations for the better management of psoriasis in women of childbearing age could improve outcomes and prognosis.
- Published
- 2021
- Full Text
- View/download PDF
8. [Translated article] Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience
- Author
-
L.M. Nieto Benito, G. Carretero, R. Rivera-Díaz, J.M. Carrascosa, E. Daudén, P. de la Cueva, A. Sahuquillo-Torralba, E. Herrera-Acosta, O. Baniandrés-Rodríguez, J.L. Lopez-Estebaranz, I. Belinchón, J. Riera-Monroig, M. Ferrán, F.J. Gómez-García, A. Mateu, L. Rodríguez, J. Vilar-Alejo, C. García-Donoso, F. Ballescá, L.-M. Velasco, R. Botella-Estrada, E. Herrera-Ceballos, D.P. Ruiz-Genao, M.A. Descalzo, and I. García-Doval
- Subjects
BIOBADADERM ,Infancia ,Psoriasis ,Registros ,Dermatology ,RL1-803 ,Internal medicine ,RC31-1245 - Abstract
Childhood-onset psoriasis generally follows an indolent course but patients with moderate or severe disease may require systemic treatment. The aim of this study was to determine the relative proportion of children and young people aged up to 21 years with moderate to severe psoriasis in the BIOBADADERM registry and to analyze the characteristics of these patients, treatments used, and adverse events. Of the 3946 patients in the registry, 24 were aged 21 years or younger. The mean age of this group when they started treatment upon registration on Biobadaderm was 16.1 years and the mean Psoriasis Area and Severity Index was 9.4. In 67% the first treatment recorded was with a conventional systemic drug. Treatment was discontinued in 14 patients (58%) due to adverse events or a loss or lack of effectiveness. In conclusion, the BIOBADADERM registry shows that young people account for a small proportion of psoriasis patients receiving systemic treatment, and they are more likely to be treated using conventional systemic drugs. Resumen: El comienzo de la psoriasis en la edad pediátrica, aunque generalmente leve, puede requerir tratamiento sistémico en las formas moderadas o graves de la enfermedad. El objetivo de este trabajo es analizar la frecuencia relativa, las características de los pacientes, el tratamiento empleado y los eventos adversos observados a partir del registro BIOBADADERM en niños y jóvenes con psoriasis moderada-grave. Del total de 3.946 pacientes del registro, se incluyen 24 pacientes menores de 21 años, con una edad media al inicio del tratamiento en BIOBADADERM de 16,1 años y un PASI medio de 9,4. El 67% de los pacientes estaban en tratamiento sistémico clásico al inicio del registro. Catorce pacientes (58%) suspendieron el tratamiento por pérdida o falta de eficacia o por eventos adversos. En conclusión, los datos del registro BIOBADADERM muestran que los menores representan un grupo muy pequeño dentro de los pacientes con psoriasis que reciben tratamiento sistémico y son manejados más frecuentemente con tratamientos clásicos.
- Published
- 2022
- Full Text
- View/download PDF
9. [Translated article] Refractory Anogenital Warts: Good Response to Photodynamic Therapy
- Author
-
B. Pinilla Martín, R. Rivera Díaz, and V. Monsálvez Honrubia
- Subjects
Dermatology ,RL1-803 ,Internal medicine ,RC31-1245 - Published
- 2022
- Full Text
- View/download PDF
10. De un anti-IL-17 a otro: dar una segunda oportunidad o cambiar de diana
- Author
-
B. Pinilla Martín, A. Sánchez Velázquez, C. Vico Alonso, and R. Rivera Díaz
- Subjects
Dermatology ,RL1-803 ,Internal medicine ,RC31-1245 - Published
- 2021
- Full Text
- View/download PDF
11. Consenso sobre las actuaciones a seguir durante la edad fértil, el embarazo, el posparto y la lactancia en pacientes con psoriasis
- Author
-
N. Martínez Sánchez, M. Velasco, R. Taberner Ferrer, S. Armesto Alonso, Isabel Belinchón, M. Ara-Martín, A. Pérez Ferriols, O. Baniandrés Rodríguez, José Manuel Carrascosa, Marta García-Bustínduy, Ricardo Ruiz-Villaverde, R. Rivera Díaz, L. Ferrándiz Pulido, E. Pérez Pascual, J.A. Martínez-López, and A. Vicente Villa
- Subjects
medicine.medical_specialty ,Consensus ,Histology ,Embarazo ,media_common.quotation_subject ,Breastfeeding ,Delphi method ,Posparto ,Fertility ,Dermatology ,Recommendations ,Pathology and Forensic Medicine ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Postpartum ,Pregnancy ,Nominal group technique ,Humans ,Psoriasis ,Medicine ,Método Delphi ,media_common ,030203 arthritis & rheumatology ,Lactancia ,business.industry ,Postpartum Period ,Nominal group ,Evidence-based medicine ,medicine.disease ,Breast Feeding ,Contraception ,Fertilidad ,Scale (social sciences) ,Family medicine ,Recomendaciones ,Female ,Delphi process ,business - Abstract
Objective To develop evidence- and experience-based recommendations for the management of psoriasis during preconception, pregnancy, postpartum, and breastfeeding. Methods The nominal group technique and the Delphi method were used. Fifteen experts (12 dermatologists, 2 of whom were appointed coordinators; 1 rheumatologist; and 2 gynecologists) were selected to form an expert panel. Following a systematic review of the literature on fertility, pregnancy, postpartum, and breastfeeding in women with psoriasis, the coordinators drew up a series of preliminary recommendations for discussion by the panel at a nominal group meeting. The experts defined the scope, sections, and intended users of the statement and prepared a final list of recommendations. Consensus was obtained using a Delphi process in which an additional 51 dermatologists rated their level of agreement with each recommendation on a scale of 1 (total disagreement) to 10 (total agreement). Consensus was defined by a score of 7 or higher assigned by at least 70% of participants. Level of evidence and strength of recommendation were reported using the Oxford Center for Evidence-Based Medicine categories. The final statement was approved by the expert panel. Results The resulting consensus statement includes 23 recommendations on preconception (fertility and contraception), pregnancy (planning, pharmacological management, and follow-up), and breastfeeding (management and follow-up). Consensus was achieved for all recommendations generated except one. Conclusions These recommendations for the better management of psoriasis in women of childbearing age could improve outcomes and prognosis. Objetivo Desarrollar recomendaciones basadas en la mejor evidencia y experiencia sobre el manejo de pacientes con psoriasis durante la edad fértil, el embarazo, el posparto y la lactancia. Métodos Se siguió la metodología de grupos nominales y Delphi. Se seleccionó un grupo director de expertos (12 dermatólogos —de los cuales 2 fueron los coordinadores—, 1 reumatólogo, 2 ginecólogos). Se realizó una revisión sistemática de la literatura sobre fertilidad, embarazo, posparto y lactancia en pacientes con psoriasis. Con esta información los coordinadores generaron una serie de recomendaciones preliminares. Todo ello se presentó y discutió con el resto de expertos en una reunión de grupo nominal donde se definió el alcance, los usuarios, los apartados del documento, y donde se generaron las recomendaciones definitivas. El grado de acuerdo con las recomendaciones se votó siguiendo la metodología Delphi, que se extendió a 51 dermatólogos más, según una escala de 1 (total desacuerdo) a 10 (total acuerdo), definiéndose el acuerdo como una puntuación = 7 por al menos el 70% de los participantes. El nivel de evidencia y el grado de recomendación se clasificaron según el modelo del Center for Evidence Based Medicine de Oxford. El documento completo final fue aprobado por el panel de expertos. Resultados Se generaron 23 recomendaciones sobre el periodo pre-concepcional (fertilidad y anticoncepción), el embarazo (planificación, manejo farmacológico y seguimiento) y la lactancia (manejo y seguimiento). Todas las recomendaciones menos una alcanzaron el nivel de acuerdo definido. Conclusiones En los pacientes con psoriasis en edad fértil estas recomendaciones pueden mejorar el manejo, los resultados y el pronóstico.
- Published
- 2021
12. De un anti-IL-17 a otro: dar una segunda oportunidad o cambiar de diana
- Author
-
C. Vico Alonso, A. Sánchez Velázquez, B. Pinilla Martín, and R. Rivera Díaz
- Subjects
RL1-803 ,General Medicine ,Dermatology ,Internal medicine ,RC31-1245 - Published
- 2021
13. Switching From One Anti-IL-17 Antibody to Another: On Trying Again or Changing the Target
- Author
-
R. Rivera Díaz, B. Pinilla Martín, C. Vico Alonso, and A. Sánchez Velázquez
- Subjects
Histology ,biology ,business.industry ,Immunology ,biology.protein ,Medicine ,Dermatology ,Interleukin 17 ,Antibody ,business ,Pathology and Forensic Medicine - Published
- 2021
14. WITHDRAWN: Refractory Anogenital Warts: Good Response to Photodynamic Therapy
- Author
-
R. Rivera Díaz, B. Pinilla Martín, and V. Monsálvez Honrubia
- Subjects
medicine.medical_specialty ,Histology ,Refractory ,business.industry ,medicine.medical_treatment ,medicine ,Photodynamic therapy ,Dermatology ,business ,Pathology and Forensic Medicine - Published
- 2021
15. Consenso sobre las actuaciones a seguir durante la edad fértil, el embarazo, el posparto y la lactancia en pacientes con psoriasis
- Author
-
L. Ferrándiz Pulido, R. Rivera Díaz, Ricardo Ruiz-Villaverde, O. Baniandrés Rodríguez, J.A. Martínez-López, M. Velasco, A. Vicente Villa, E. Pérez Pascual, José Manuel Carrascosa, S. Armesto Alonso, A. Pérez Ferriols, Marta García-Bustínduy, N. Martínez Sánchez, Isabel Belinchón, M. Ara-Martín, and R. Taberner Ferrer
- Subjects
Fertility ,Pregnancy ,Postpartum ,RL1-803 ,Breastfeeding ,Psoriasis ,Delphi process ,General Medicine ,Dermatology ,Internal medicine ,RC31-1245 - Abstract
Objetivo Desarrollar recomendaciones basadas en la mejor evidencia y experiencia sobre el manejo de pacientes con psoriasis durante la edad fértil, el embarazo, el posparto y la lactancia. Métodos Se siguió la metodología de grupos nominales y Delphi. Se seleccionó un grupo director de expertos (12 dermatólogos —de los cuales 2 fueron los coordinadores—, 1 reumatólogo, 2 ginecólogos). Se realizó una revisión sistemática de la literatura sobre fertilidad, embarazo, posparto y lactancia en pacientes con psoriasis. Con esta información los coordinadores generaron una serie de recomendaciones preliminares. Todo ello se presentó y discutió con el resto de expertos en una reunión de grupo nominal donde se definió el alcance, los usuarios, los apartados del documento, y donde se generaron las recomendaciones definitivas. El grado de acuerdo con las recomendaciones se votó siguiendo la metodología Delphi, que se extendió a 51 dermatólogos más, según una escala de 1 (total desacuerdo) a 10 (total acuerdo), definiéndose el acuerdo como una puntuación = 7 por al menos el 70% de los participantes. El nivel de evidencia y el grado de recomendación se clasificaron según el modelo del Center for Evidence Based Medicine de Oxford. El documento completo final fue aprobado por el panel de expertos. Resultados Se generaron 23 recomendaciones sobre el periodo pre-concepcional (fertilidad y anticoncepción), el embarazo (planificación, manejo farmacológico y seguimiento) y la lactancia (manejo y seguimiento). Todas las recomendaciones menos una alcanzaron el nivel de acuerdo definido. Conclusiones En los pacientes con psoriasis en edad fértil estas recomendaciones pueden mejorar el manejo, los resultados y el pronóstico. Objective To develop evidence- and experience-based recommendations for the management of psoriasis during preconception, pregnancy, postpartum, and breastfeeding. Methods The nominal group technique and the Delphi method were used. Fifteen experts (12 dermatologists, 2 of whom were appointed coordinators; 1 rheumatologist; and 2 gynecologists) were selected to form an expert panel. Following a systematic review of the literature on fertility, pregnancy, postpartum, and breastfeeding in women with psoriasis, the coordinators drew up a series of preliminary recommendations for discussion by the panel at a nominal group meeting. The experts defined the scope, sections, and intended users of the statement and prepared a final list of recommendations. Consensus was obtained using a Delphi process in which an additional 51 dermatologists rated their level of agreement with each recommendation on a scale of 1 (total disagreement) to 10 (total agreement). Consensus was defined by a score of 7 or higher assigned by at least 70% of participants. Level of evidence and strength of recommendation were reported using the Oxford Center for Evidence-Based Medicine categories. The final statement was approved by the expert panel. Results The resulting consensus statement includes 23 recommendations on preconception (fertility and contraception), pregnancy (planning, pharmacological management, and follow-up), and breastfeeding (management and follow-up). Consensus was achieved for all recommendations generated except one. Conclusions These recommendations for the better management of psoriasis in women of childbearing age could improve outcomes and prognosis.
- Published
- 2020
16. Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016
- Author
-
I. Belinchón Romero, M. Alsina Gibert, E. Daudén Tello, F.J. Gómez-García, R. Rivera Díaz, Carlos Ferrándiz, Miguel Ángel Descalzo, Ignacio García-Doval, C. Muñoz Santos, Enrique Herrera-Ceballos, A. González Quesada, M.V. Mendiola Fernández, J.L. Sánchez-Carazo, J.M. Carrascosa Carrillo, M. Ferrán Farrés, José L. López-Estebaranz, Mar Llamas-Velasco, G. Carretero Hernández, D.P. Ruiz Genao, and P. de la Cueva-Dobao
- Subjects
030203 arthritis & rheumatology ,Drug ,medicine.medical_specialty ,Histology ,business.industry ,media_common.quotation_subject ,Dermatology ,medicine.disease ,Systemic therapy ,Pathology and Forensic Medicine ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Drug withdrawal ,Liver disease ,0302 clinical medicine ,Internal medicine ,Diabetes mellitus ,Psoriasis ,medicine ,Observational study ,Adverse effect ,business ,media_common - Abstract
Introduction and objectives Biologic drugs are usually prescribed as second-line treatment for psoriasis, that is, after the patient has first been treated with a conventional psoriasis drug. There are, however, cases where, depending on the characteristics of the patient or the judgement of the physician, biologics may be chosen as first-line therapy. No studies to date have analyzed the demographics or clinical characteristics of patients in this setting or the safety profile of the agents used. The main aim of this study was to characterize these aspects of first-line biologic therapy and compare them to those observed for patients receiving biologics as second-line therapy. Material and method We conducted an observational study of 181 patients treated in various centers with a systemic biologic drug as first-line treatment for moderate to severe psoriasis between January 2008 and November 2016. All the patients were registered in the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology. Results The characteristics of the first- and second-line groups were very similar, although the patients receiving a biologic as first-line treatment for their psoriasis were older. No differences were observed for disease severity (assessed using the PASI) or time to diagnosis. Hypertension, diabetes, and liver disease were all more common in the first-line group. There were no differences between the groups in terms of reasons for drug withdrawal or occurrence of adverse effects. Conclusions No major differences were found between patients with psoriasis receiving biologic drugs as first- or second-line therapy, a finding that provides further evidence of the safety of biologic therapy in patients with psoriasis.
- Published
- 2018
17. Acquired Dermal Melanocytosis on the Back of a Patient With Psoriasis
- Author
-
R. Rivera-Díaz, S. Burillo-Martínez, L. Flores, and J.L. Rodríguez Peralto
- Subjects
medicine.medical_specialty ,Histology ,business.industry ,Psoriasis ,medicine ,Dermatology ,medicine.disease ,business ,Pathology and Forensic Medicine - Published
- 2018
18. Can Psoriasis Produce Irreversible Alopecia?
- Author
-
F. Vanaclocha Sebastian, R. Rivera Díaz, J.L. Rodríguez Peralto, and C. Gutiérrez García-Rodrigo
- Subjects
medicine.medical_specialty ,Histology ,business.industry ,Dermatology ,medicine.disease ,Pathology and Forensic Medicine ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Psoriasis ,medicine ,030211 gastroenterology & hepatology ,Young adult ,business - Published
- 2016
19. ¿La psoriasis produce alopecia irreversible?
- Author
-
C. Gutiérrez García-Rodrigo, J.L. Rodríguez Peralto, R. Rivera Díaz, and F. Vanaclocha Sebastian
- Subjects
030207 dermatology & venereal diseases ,03 medical and health sciences ,medicine.medical_specialty ,0302 clinical medicine ,business.industry ,030220 oncology & carcinogenesis ,Medicine ,General Medicine ,business ,Dermatology - Published
- 2016
20. Deep Vein Thrombosis in A Patient with Lepromatous Leprosy Receiving Thalidomide to Treat Leprosy Reaction
- Author
-
M. Burgués-Calderón, L. Fuertes, Francisco Vanaclocha, M. Villar-Buill, G. Hebe Petiti-Martin, I. de la Hera, and R. Rivera-Díaz
- Subjects
medicine.medical_specialty ,Lepromatous leprosy ,Histology ,integumentary system ,business.industry ,Deep vein ,Leprostatic agent ,Dermatology ,medicine.disease ,Thrombosis ,Pathology and Forensic Medicine ,Surgery ,Thalidomide ,Venous thrombosis ,medicine.anatomical_structure ,Prednisone ,medicine ,Leprosy ,skin and connective tissue diseases ,business ,medicine.drug - Abstract
Thalidomide is the treatment of choice for severe or recurrent erythema nodosum leprosum. Its use has been associated with deep vein thrombosis in patients with blood disorders, however, particularly when used in combination with corticosteroids or chemotherapy. We describe a case of deep vein thrombosis in a 43-year-old man with lepromatous leprosy who was being treated with thalidomide and prednisone for a type 2 leprosy reaction (erythema nodosum leprosum); the patient also had transiently positive antiphospholipid antibody results. We stress the importance of considering deep vein thrombosis, a potentially fatal complication, in dermatology patients treated with thalidomide.
- Published
- 2013
21. Trombosis venosa profunda en paciente con lepra lepromatosa tratado con talidomida por leprorreacción
- Author
-
M. Villar-Buill, M. Burgués-Calderón, R. Rivera-Díaz, I. de la Hera, G. Hebe Petiti-Martin, Francisco Vanaclocha, and L. Fuertes
- Subjects
medicine.medical_specialty ,Chemotherapy ,Lepromatous leprosy ,integumentary system ,business.industry ,Deep vein ,medicine.medical_treatment ,General Medicine ,medicine.disease ,Thrombosis ,Dermatology ,Surgery ,Thalidomide ,medicine.anatomical_structure ,Prednisone ,medicine ,Leprosy ,skin and connective tissue diseases ,business ,Complication ,medicine.drug - Abstract
Thalidomide is the treatment of choice for severe or recurrent erythema nodosum leprosum. Its use has been associated with deep vein thrombosis in patients with blood disorders, however, particularly when used in combination with corticosteroids or chemotherapy. We describe a case of deep vein thrombosis in a 43-year-old man with lepromatous leprosy who was being treated with thalidomide and prednisone for a type 2 leprosy reaction (erythema nodosum leprosum); the patient also had transiently positive antiphospholipid antibody results. We stress the importance of considering deep vein thrombosis, a potentially fatal complication, in dermatology patients treated with thalidomide.
- Published
- 2013
22. Penile Paraffinoma: Should We Perform Ultrasound?
- Author
-
Carlos Morales-Raya, Fátima Tous-Romero, Alba Calleja-Algarra, and R. Rivera-Díaz
- Subjects
Adult ,Male ,medicine.medical_specialty ,Histology ,Penile Diseases ,business.industry ,Injections, Subcutaneous ,Ultrasound ,Dermatology ,Cosmetic Techniques ,Plastic Surgery Procedures ,Giant Cells ,030218 nuclear medicine & medical imaging ,Pathology and Forensic Medicine ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Skin Ulcer ,medicine ,Humans ,Mineral Oil ,Radiology ,business ,Ultrasonography - Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.